German chemical and pharmaceutical company Bayer is to implement a restructuring program from January 1, 1997. The reorganization includes the separation of the marketing activities of its pharmaceuticals and chemicals business, and the 21 business units will be regrouped to form five divisions instead of the current six. The changes will be made on the basis of the new "Guidelines for the strategic alignment of the Bayer group."
The firm is not alone in restructuring; Hoechst is also undergoing major changes, which are more radical than those at Bayer. Hoechst is separating out its businesses with the aim of making initial public offerings. Bayer, however, plans to remain fully integrated, which is viewed as old-fashioned by some observers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze